|
業務類別
|
Drug Manufacturers - General |
|
業務概覽
|
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio. |
| 公司地址
| One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799 |
| 電話號碼
| +1 805 447-1000 |
| 傳真號碼
| +1 805 447-1010 |
| 公司網頁
| https://www.amgen.com |
| 員工數量
| 31500 |
| Mr. Robert A. Bradway |
Chairman of the Board, President and Chief Executive Officer |
美元 1.87M |
13/02/2026 |
| Mr. Jonathan P. Graham |
Executive Vice President, General Counsel and Secretary |
-- |
13/02/2026 |
| Mr. Murdo Gordon |
Executive Vice President, Global Commercial Operations |
美元 1.20M |
13/02/2026 |
| Mr. Esteban Santos |
Executive Vice President, Operations |
-- |
13/02/2026 |
| Mr. Matthew C. Busch |
Vice President, Finance and Chief Accounting Officer |
-- |
13/02/2026 |
| Dr. David M. Reese, M.D. |
Executive Vice President and Chief Technology Officer |
美元 1.27M |
13/02/2026 |
| Mr. Peter H. Griffith |
Executive Vice President and Chief Financial Officer |
美元 1.13M |
13/02/2026 |
| Ms. Nancy A. Grygiel |
Senior Vice President and Chief Compliance Officer |
-- |
13/02/2026 |
| Mr. Derek Miller |
Senior Vice President, Human Resources |
-- |
13/02/2026 |
| Dr. James E. Bradner, M.D. |
Executive Vice President, Research and Development |
美元 1.21M |
13/02/2026 |
| Ms. Rachna Khosla |
Senior Vice President, Business Development |
-- |
13/02/2026 |
|
|
| Ms. Amy E. Miles |
Independent Director |
13/02/2026 |
| Mr. Charles M. Holley, Jr |
Independent Director |
13/02/2026 |
| Ms. Ellen J. Kullman |
Independent Director |
13/02/2026 |
| Mr. Robert A. Eckert |
Lead Independent Director |
13/02/2026 |
| Mr. Robert A. Bradway |
Chairman of the Board, President and Chief Executive Officer |
13/02/2026 |
| Professor Dr. Tyler E. Jacks, PhD |
Independent Director |
13/02/2026 |
| Mr. Greg C. Garland |
Independent Director |
13/02/2026 |
| Dr. Wanda M. Austin |
Independent Director |
13/02/2026 |
| Dr. Brian J. Druker, M.D. |
Independent Director |
13/02/2026 |
| Mr. Michael V. Drake |
Independent Director |
13/02/2026 |
| Dr. S. Omar Ishrak |
Independent Director |
13/02/2026 |
| Ms. Mary E. Klotman |
Independent Director |
13/02/2026 |
|
|
|
|
